genedrive plc (GDR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, genedrive plc (GDR) has a cash flow conversion efficiency ratio of -1.421x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.04 Million ≈ $-248.70 USD) by net assets (GBX1.44 Million ≈ $174.96 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GDR net asset quality index to measure how much of total assets are equity-financed.
genedrive plc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how genedrive plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GDR cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
genedrive plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of genedrive plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REVEZ CORPORATION LTD.
F:7IQ
|
N/A |
|
Caffyns PLC
LSE:CFYN
|
-0.002x |
|
Empresaria Group plc
LSE:EMR
|
0.198x |
|
Inspired Plc
LSE:INSE
|
0.109x |
|
Shearwater Group plc
LSE:SWG
|
-0.070x |
|
DSW Capital PLC
LSE:DSW
|
-0.032x |
|
Matahari Department Store Tbk
JK:LPPF
|
0.688x |
|
Angus Energy PLC
LSE:ANGS
|
0.034x |
Annual Cash Flow Conversion Efficiency for genedrive plc (2006–2025)
The table below shows the annual cash flow conversion efficiency of genedrive plc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see GDR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX1.44 Million ≈ $174.96 |
GBX-5.10 Million ≈ $-620.64 |
-3.547x | -404.51% |
| 2024-06-30 | GBX5.36 Million ≈ $652.04 |
GBX-3.77 Million ≈ $-458.46 |
-0.703x | +62.00% |
| 2023-06-30 | GBX2.04 Million ≈ $248.33 |
GBX-3.78 Million ≈ $-459.43 |
-1.850x | -125.18% |
| 2022-06-30 | GBX5.61 Million ≈ $682.70 |
GBX-4.61 Million ≈ $-560.90 |
-0.822x | +43.07% |
| 2021-06-30 | GBX3.59 Million ≈ $437.04 |
GBX-5.18 Million ≈ $-630.74 |
-1.443x | -227.33% |
| 2020-06-30 | GBX-3.34 Million ≈ $-406.62 |
GBX-3.79 Million ≈ $-460.89 |
1.133x | -22.43% |
| 2019-06-30 | GBX-2.48 Million ≈ $-301.50 |
GBX-3.62 Million ≈ $-440.57 |
1.461x | +39.82% |
| 2018-06-30 | GBX-2.44 Million ≈ $-296.51 |
GBX-2.55 Million ≈ $-309.90 |
1.045x | +295.77% |
| 2017-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-1.84 Million ≈ $-223.51 |
-0.534x | +42.77% |
| 2016-06-30 | GBX3.75 Million ≈ $456.63 |
GBX-3.50 Million ≈ $-425.97 |
-0.933x | -169.33% |
| 2015-06-30 | GBX9.54 Million ≈ $1.16K |
GBX-3.31 Million ≈ $-402.24 |
-0.346x | -244.58% |
| 2014-06-30 | GBX10.86 Million ≈ $1.32K |
GBX-1.09 Million ≈ $-132.86 |
-0.101x | -97.99% |
| 2013-06-30 | GBX12.05 Million ≈ $1.47K |
GBX-612.00K ≈ $-74.46 |
-0.051x | -66.01% |
| 2012-06-30 | GBX8.86 Million ≈ $1.08K |
GBX-271.00K ≈ $-32.97 |
-0.031x | +72.95% |
| 2011-06-30 | GBX6.18 Million ≈ $752.17 |
GBX-699.00K ≈ $-85.05 |
-0.113x | +8.53% |
| 2010-06-30 | GBX5.78 Million ≈ $703.75 |
GBX-715.00K ≈ $-86.99 |
-0.124x | -118.01% |
| 2009-06-30 | GBX2.76 Million ≈ $335.81 |
GBX1.89 Million ≈ $230.45 |
0.686x | +256.66% |
| 2008-06-30 | GBX2.58 Million ≈ $314.15 |
GBX-1.13 Million ≈ $-137.61 |
-0.438x | -41.49% |
| 2007-06-30 | GBX2.60 Million ≈ $315.98 |
GBX-804.00K ≈ $-97.82 |
-0.310x | +61.17% |
| 2006-06-30 | GBX1.09 Million ≈ $133.23 |
GBX-873.00K ≈ $-106.22 |
-0.797x | -- |
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more